Wells Fargo Remains a Hold on Conmed (CNMD)
Conmed Analyst Ratings
Needham Maintains ConMed(CNMD.US) With Buy Rating, Maintains Target Price $97
Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)
Wells Fargo Maintains ConMed(CNMD.US) With Hold Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Conmed (CNMD) and Ironwood Pharma (IRWD)
Conmed (CNMD) Gets a Hold From Wells Fargo
Conmed Performance Analysis: Hold Rating Justified Amid Supply Chain Resolutions and Gross Margin Adjustments
Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $80
Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating
Stifel Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $76
Stifel Nicolaus Sticks to Their Buy Rating for Conmed (CNMD)
Wells Fargo Maintains ConMed(CNMD.US) With Hold Rating, Cuts Target Price to $71
Needham Maintains Buy on Conmed, Lowers Price Target to $97
Conmed Analyst Ratings
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Conmed (CNMD)
Needham Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $97
Conmed Price Target Cut to $106.00/Share From $107.00 by Needham
Conmed Analyst Ratings
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Conmed (CNMD) and PTC Therapeutics (PTCT)